This was all #$%$ to me. Aetna is just going to make the process for pre-auth a little more difficult, also noting that they would continue to cover members who had used Acthar in the prior 12 months. Fear mongering and heavy hands pushed this thing down. Their October earnings are going to crush, and this thing will be back up above 40 in short order.
I nibbled a little yesterday at $28.40 and think that'll be good for an easy 50% gain in a month. I don't think I have the stomach to hold it long-term since it's been majorly dropped 3 or 4 times in the past 6 months, all by ridiculous (and potentially fraudulent, IMO) reports from Citron. Such is the risk of a [mostly] "one trick pony" pharma, I guess
I agree with every point you make. I made just under 50% with it during July 2011 and I get a vicarious thrill watching it now. You got in at the right time and I agree it's just too risky to stay for too long. It can seduce with its explosive potential, but the fact it's a one trick pony argues on the side of caution. Good luck riding that bucking bronco!